Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Consolidated revenue from operations stood at Rs. 111.05 crore
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated
